Top

Published in:

01-12-2012 | Article

Depletion of homeodomain-interacting protein kinase 3 impairs insulin secretion and glucose tolerance in mice

Authors: N. Shojima, K. Hara, H. Fujita, M. Horikoshi, N. Takahashi, I. Takamoto, M. Ohsugi, H. Aburatani, M. Noda, N. Kubota, T. Yamauchi, K. Ueki, T. Kadowaki

Published in: Diabetologia | Issue 12/2012

Abstract

Aims/hypothesis

Insufficient insulin secretion and reduced pancreatic beta cell mass are hallmarks of type 2 diabetes. Here, we focused on a family of serine-threonine kinases known as homeodomain-interacting protein kinases (HIPKs). HIPKs are implicated in the modulation of Wnt signalling, which plays a crucial role in transcriptional activity, and in pancreas development and maintenance. The aim of the present study was to characterise the role of HIPKs in glucose metabolism.

Methods

We used RNA interference to characterise the role of HIPKs in regulating insulin secretion and transcription activity. We conducted RT-PCR and western blot analyses to analyse the expression and abundance of HIPK genes and proteins in the islets of high-fat diet-fed mice. Glucose-induced insulin secretion and beta cell proliferation were measured in islets from Hipk3 ^−/− mice, which have impaired glucose tolerance owing to an insulin secretion deficiency. The abundance of pancreatic duodenal homeobox (PDX)-1 and glycogen synthase kinase (GSK)-3β phosphorylation in Hipk3 ^−/− islets was determined by immunohistology and western blot analyses.

Results

We found that HIPKs regulate insulin secretion and transcription activity. Hipk3 expression was most significantly increased in the islets of high-fat diet-fed mice. Furthermore, glucose-induced insulin secretion and beta cell proliferation were decreased in the islets of Hipk3 ^−/− mice. Levels of PDX1 and GSK-3β phosphorylation were significantly decreased in Hipk3 ^−/− islets.

Conclusions/interpretation

Depletion of HIPK3 impairs insulin secretion and glucose tolerance. Decreased levels of HIPK3 may play a substantial role in the pathogenesis of type 2 diabetes.

Available only for authorised users

Kahn CR (1994) Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066–1084PubMedCrossRef

Accili D (2004) Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic. Diabetes 53:1633–1642PubMedCrossRef

Doria A, Patti ME, Kahn CR (2008) The emerging genetic architecture of type 2 diabetes. Cell Metab 8:186–200PubMedCrossRef

Rulifson IC, Karnik SK, Heiser PW et al (2007) Wnt signaling regulates pancreatic beta cell proliferation. Proc Nat Acad Sci USA 104:6247–6252PubMedCrossRef

Schinner S, Ulgen F, Papewalis C et al (2008) Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules. Diabetologia 51:147–154PubMedCrossRef

Liu Z, Habener JF (2010) Wnt signaling in pancreatic islets. Adv Exp Med Biol 654:391–419PubMedCrossRef

Welters HJ, Kulkarni RN (2008) Wnt signaling: relevance to beta-cell biology and diabetes. Trends Endocrinol Metab 19:349–355PubMedCrossRef

Jin T (2008) The WNT signalling pathway and diabetes mellitus. Diabetologia 51:1771–1780PubMedCrossRef

Schinner S, Willenberg HS, Schott M, Scherbaum WA (2009) Pathophysiological aspects of Wnt-signaling in endocrine disease. Eur J Endocrinol 160:731–737PubMedCrossRef

10.

Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810PubMedCrossRef

11.

Moon RT, Kohn AD, de Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5:691–701PubMedCrossRef

12.

Liu Z, Tanabe K, Bernal-Mizrachi E, Permutt MA (2008) Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation. Diabetologia 51:623–631PubMedCrossRef

13.

Tanabe K, Liu Z, Patel S et al (2009) Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol 6:e37CrossRef

14.

Liu Y, Tanabe K, Baronnier D et al (2010) Conditional ablation of Gsk-3β in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice. Diabetologia 53:2600–2610PubMedCrossRef

15.

Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J et al (2004) Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev 18:816–829PubMedCrossRef

16.

Wei G, Ku S, Ma G et al (2007) HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci USA 104:13040–13045PubMedCrossRef

17.

Kim EA, Kim JE, Sung KS et al (2010) Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for phosphorylation and proteasomal degradation. Biochem Biophys Res Commun 394:966–971PubMedCrossRef

18.

Swarup S, Verheyen EM (2011) Drosophila homeodomain-interacting protein kinase inhibits the Skp1-Cul1-F-box E3 ligase complex to dually promote Wingless and Hedgehog signaling. Proc Natl Acad Sci USA 108:9887–9892PubMedCrossRef

19.

Lee W, Swarup S, Chen J, Ishitani T, Verheyen EM (2009) Homeodomain-interacting protein kinases (Hipks) promote Wnt/Wg signaling through stabilization of beta-catenin/Arm and stimulation of target gene expression. Development 136:241–251PubMedCrossRef

20.

Louie SH, Yang XY, Conrad WH et al (2009) Modulation of the beta-catenin signaling pathway by the dishevelled-associated protein Hipk1. PLoS One 4:e4310PubMedCrossRef

21.

Hisaka H, Ezan J, Itoh K, Li X, Klymkowsky MW, Sokol SY (2010) Regulation of TCF3 by Wnt-dependent phosphorylation during vertebrate axis specification. Dev Cell 19:521–532CrossRef

22.

Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y (1998) Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 273:25875–25879PubMedCrossRef

23.

D’Orazi G, Cecchinelli B, Bruno T et al (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Cell Biol 4:11–19

24.

Hofmann TG, Moller A, Sirma H et al (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4:1–10PubMedCrossRef

25.

Kondo S, Lu Y, Debbas M et al (2003) Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci USA 100:5431–5436PubMedCrossRef

26.

Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH (2003) Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 115:177–186PubMedCrossRef

27.

Choi CY, Kim YH, Kim YO et al (2005) Phosphorylation by the DHIPK2 protein kinase modulates the corepressor activity of Groucho. J Biol Chem 280:21427–21436PubMedCrossRef

28.

Boucher M, Simoneau ML, Edlund H (2009) The homeodomain-interacting protein kinase 2 regulates insulin promoter factor-1/pancreatic duodenal homeobox-1 transcriptional activity. Endocrinology 150:87–97PubMedCrossRef

29.

Jonsson J, Carlsson L, Edlund T, Edlund H (1994) Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371:606–609PubMedCrossRef

30.

Offield MF, Jetton TL, Labosky PA et al (1996) PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122:983–995PubMed

31.

Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF (1997) Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 15:106–110PubMedCrossRef

32.

Moilanen AM, Karvonen U, Poukka H, Janne OA, Palvimo JJ (1998) Activation of androgen receptor function by a novel nuclear protein kinase. Mol Biol Cell 9:2527–2543PubMed

33.

Rochat-Steiner V, Becker K, Micheau O, Schneider P, Burns K, Tschopp J (2000) FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. J Exp Med 192:1165–1174PubMedCrossRef

34.

Curtin JF, Cotter TG (2004) JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. J Biol Chem 279:17090–17100PubMedCrossRef

35.

Lan HC, Li HJ, Lin G, Lai PY, Chung BC (2007) Cyclic AMP stimulates SF-1-dependent CYP11A1 expression through homeodomain-interacting protein kinase 3-mediated Jun N-terminal kinase and c-Jun phosphorylation. Mol Cell Biol 27:2027–2036PubMedCrossRef

36.

Sierra OL, Towler DA (2010) Runx2 trans-activation mediated by the MSX2-interacting nuclear target requires homeodomain interacting protein kinase-3. Mol Endocrinol 24:1478–1497PubMedCrossRef

37.

Inoue T, Kagawa T, Inoue-Mochita M et al (2010) Involvement of the Hipk family in regulation of eyeball size, lens formation and retinal morphogenesis. FEBS Lett 584:3233–3238PubMedCrossRef

38.

Scopsi L, Wang BL, Larsson LI (1986) Nonspecific immunocytochemical reactions with certain neurohormonal peptides and basic peptide Sequences. J Histochem Cytochem 34:1469–1475PubMedCrossRef

39.

Noda M, Yamashita S, Takahashi N et al (2002) Switch to anaerobic glucose metabolism with NADH accumulation in the beta-cell model of mitochondrial diabetes. Characteristics of betaHC9 cells deficient in mitochondrial DNA transcription. J Biol Chem 277:41817–41826PubMedCrossRef

40.

Takahashi N, Hatakeyama H, Okado H et al (2004) Sequential exocytosis of insulin granules is associated with redistribution of SNAP25. J Cell Biol 165:255–262PubMedCrossRef

41.

Isono K, Nemoto K, Li Y et al (2006) Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals. Mol Cell Biol 26:2758–2771PubMedCrossRef

42.

An R, da Silva Xavier G, Semplici F et al (2010) Pancreatic and duodenal homeobox 1 (PDX1) phosphorylation at serine-269 is HIPK2-dependent and affects PDX1 subnuclear localization. Biochem Biophys Res Commun 399:155–161PubMedCrossRef

43.

Gerrish K, Gannon M, Shih D et al (2000) Pancreatic beta cell-specific transcription of the pdx-1 gene. The role of conserved upstream control regions and their hepatic nuclear factor 3beta sites. J Biol Chem 275:3485–3492PubMedCrossRef

44.

Gerrish K, van Velkinburgh JC, Stein R (2004) Conserved transcriptional regulatory domains of the pdx-1 gene. Mol Endocrinol 18:533–548PubMedCrossRef

45.

van Velkinburgh JC, Samaras SE, Gerrish K, Artner I, Stein R (2005) Interactions between areas I and II direct pdx-1 expression specifically to islet cell types of the mature and developing pancreas. J Biol Chem 280:38438–38444PubMedCrossRef

46.

Fujino T, Asaba H, Kang MJ et al (2003) Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci USA 100:229–234PubMedCrossRef

47.

Murtaugh LC, Law AC, Dor Y, Melton DA (2005) Beta-catenin is essential for pancreatic acinar but not islet development. Development 132:4663–4674PubMedCrossRef

48.

Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464PubMedCrossRef

49.

Ni Z, Anini Y, Fang X, Mills G, Brubaker PL, Jin T (2003) Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem 278:1380–1387PubMedCrossRef

Title: Depletion of homeodomain-interacting protein kinase 3 impairs insulin secretion and glucose tolerance in mice
Authors: N. Shojima
K. Hara
H. Fujita
M. Horikoshi
N. Takahashi
I. Takamoto
M. Ohsugi
H. Aburatani
M. Noda
N. Kubota
T. Yamauchi
K. Ueki
T. Kadowaki
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 12/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2711-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 12/2012

Acarbose treatment enhances mid-regional pro-atrial natriuretic peptide concentrations in non-diabetic individuals: further evidence for a common cardiometabolic pathway?

The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial

Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance

Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

TCF7L2 promotes beta cell regeneration in human and mouse pancreas

A two-step screening algorithm including fasting plasma glucose measurement and a risk estimation model is an accurate strategy for detecting gestational diabetes mellitus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials